Biotechnology Value Fund, L.P. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	2/25/2003 2:57:36 PM
From: scaram(o)uche	of 4974

Amgen sees sales growth of 30-32 percent to 2005 Tuesday February 25, 2:42 pm ET LOS ANGELES, Feb 25 (Reuters) - Amgen Inc. (NasdaqNM:AMGN - News), the world's largest biotechnology company, on Tuesday forecast global product sales growth of up to 32 percent annually through 2005 and reaffirmed 2003 earnings targets. ADVERTISEMENT Amgen, which is holding an investor conference in Thousand Oaks, California, on Tuesday, also said it expects adjusted annual earnings per share growth of 25 percent to 27 percent from 2002 to 2005. The adjusted results do not include a charge of 15 cents to 20 cents a share related to Amgen's acquisition of Immunex. In December, Amgen Chief Executive Kevin Sharer projected the company's 2003 EPS would rise by as much as 29 percent to between $1.70 and $1.80 from $1.39 in 2002, while sales growth was seen as high as 47 percent. The company said it expects sales to increase at a compound annual growth rate in the range of 30 percent to 32 percent from 2002 to 2005.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next